Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Next Previous
Search
Trial Profile

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational
  • Acronyms EASE LID 2
  • Sponsors Adamas Pharmaceuticals

    • Most Recent Events

    • 26 Apr 2022 Results of pooled analysis from EASE LID, EASE LID 2 and EASE LID 3; valuating potential utility of Amantadine for persons with parkinson disease under consideration for device aided therapy, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
    • 11 Sep 2020 According to an Adamas Pharmaceuticals media release, data from this trial will be presented at Movement Disorder Society (MDS) 2020 Virtual Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top